CC-90003, a covalent ERK1/2 inhibitor, disrupts signaling pathways and impacts cell growth and survival, particularly in KRAS-mutant cells (Aronchik et al., 2019), indicating its therapeutic potential in colorectal cancer. The gene discussed is KRAS; the disease is colorectal cancer.